Core Insights - DaVita Inc. reported adjusted earnings per share (EPS) of $2.00 for Q1 2025, a decrease of 11.5% year over year, but exceeded the Zacks Consensus Estimate by 14.3% [1] - The company's revenues reached $3.22 billion, marking a 4.9% increase year over year and surpassing the Zacks Consensus Estimate by 0.4% [2] Revenue Analysis - Revenue per treatment was $400.1 million, up 4.1% year over year, driven by the inclusion of phosphate binders in the payment system and other rate increases [3] - Dialysis patient service revenues were $3.10 billion, reflecting a 5.5% year-over-year increase, while other revenues decreased by 6.6% to $120.5 million [5] Treatment and Patient Metrics - Total U.S. dialysis treatments for Q1 2025 were 7,040,519, averaging 91,793 treatments per day, a slight sequential increase of 0.01% [6] - As of March 31, 2025, DaVita served approximately 282,000 patients across 3,173 outpatient dialysis centers [6] Operational Changes - During Q1 2025, DaVita acquired one, opened six, and closed four dialysis centers in the U.S., and also acquired one and closed two centers internationally [7] Financial Performance - Gross profit declined by 0.8% year over year to $983.9 million, with a gross margin contraction of 177 basis points to 30.5% [8] - General & administrative expenses rose by 3.2% year over year to $374.1 million, while adjusted operating profit fell by 3.1% to $609.8 million [9] Cash Flow and Debt - DaVita ended Q1 2025 with cash and cash equivalents of $511.9 million, down from $845.9 million at the end of 2024, and total debt increased to $9.74 billion [10] - Net cash provided by operating activities was $180 million, compared to a net cash used of $134.8 million in the previous year [11] Guidance and Outlook - The company reiterated its adjusted EPS outlook for 2025, projecting a range of $10.20 to $11.30, with the Zacks Consensus Estimate at $10.76 [12] - Management expressed optimism regarding the revenue contribution from phosphate binders to the full-year operating income [14] Market Reaction - DaVita's shares fell nearly 0.4% in after-hours trading following the earnings report [4]

Company Performance - DaVita HealthCare reported quarterly earnings of $2 per share, exceeding the Zacks Consensus Estimate of $1.75 per share, but down from $2.38 per share a year ago, representing an earnings surprise of 14.29% [1] - The company posted revenues of $3.22 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.38% and up from $3.07 billion year-over-year [2] - Over the last four quarters, DaVita has surpassed consensus EPS estimates three times and topped revenue estimates four times [2] Stock Outlook - DaVita HealthCare shares have declined approximately 3.9% since the beginning of the year, compared to a 3.8% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $2.89 on revenues of $3.3 billion, and for the current fiscal year, it is $10.76 on revenues of $13.46 billion [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which DaVita belongs, is currently ranked in the top 18% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can significantly impact stock performance [5][8]

Financial Data and Key Metrics Changes - First quarter adjusted operating income was $439 million, adjusted EPS was $2, and free cash flow was negative $45 million, with adjusted operating income above guidance due to strong expense management and international performance [18][25] - Revenue per treatment increased by $4, with approximately $10 attributed to new reimbursement for phosphate binders, partially offset by a $5 decline due to seasonal patient responsibility [21][40] - Patient care cost per treatment increased by $7 sequentially, driven by new costs associated with phosphate binders [21] Business Line Data and Key Metrics Changes - Adjusted international operating income increased by $29 million compared to the previous quarter, with a strong performance across various markets [22] - Integrated Kidney Care (IKC) reported operating losses of $29 million, in line with expectations, with seasonally stronger performance anticipated in the second half of the year [22] Market Data and Key Metrics Changes - Treatments per day declined by 40 basis points year-over-year and were approximately 50 basis points below forecast, primarily due to a higher missed treatment rate from a severe flu season [19] - The company expects an approximately 50 basis point decline in treatments for the year, influenced by flu-related impacts and the cyber incident [20] Company Strategy and Development Direction - The company remains committed to investing available capital in innovation and high-return growth opportunities, including a recent acquisition in Latin America [13] - The capital allocation strategy includes returning capital to shareholders through share repurchases, with approximately $680 million repurchased since the last earnings call [13] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of operations despite a cybersecurity incident that disrupted parts of the business, with uninterrupted patient care maintained [9][10] - The company reiterated its 2025 guidance range for adjusted operating income and adjusted EPS, despite headwinds from the cyber incident and a challenging flu season [16][25] Other Important Information - The company launched a community-based collaboration with the YMCA to support chronic kidney disease education and prevention, with early results showing 30% of participants screened had previously undiagnosed CKD [6][7] - The company is addressing regulatory and legal follow-ups related to the cyber incident, with most costs expected to be one-time items recognized in the second quarter [10][31] Q&A Session Summary Question: Impact of flu and cyber attack on treatment volume - The flu had a significant impact on the full year treatment volume, accounting for more than half of the 50 basis point revision, while the cyber incident contributed to a loss of approximately 500 admissions [29][30] Question: Costs related to the cyber attack - Majority of costs from the cyber attack will be one-time items recognized in Q2, with some direct costs likely covered by insurance and not included in adjusted operating income [31] Question: Phosphate binders uptake and drug mix - The mix leaned towards iron-based binders, leading to an increase in guidance for operating income contribution from phosphate binders to the upper end of the previous range [32][33] Question: Revenue per treatment expectations - Revenue per treatment is expected to remain within the previously guided range of 4.5% to 5.5%, with half of the increase coming from core business and half from orals [43][44] Question: International market performance - International operations had a strong quarter, with a significant year-over-year increase, and the company feels positive about the new acquisition's performance [58]

Financial Data and Key Metrics Changes - First quarter adjusted operating income was $439 million, adjusted EPS was $2, and free cash flow was negative $45 million, with adjusted operating income above previous guidance due to strong expense management and international performance [18][25] - Revenue per treatment increased by $4, with approximately $10 attributed to new reimbursement for phosphate binders, partially offset by a $5 decline due to seasonal patient responsibility [21][39] - Patient care cost per treatment increased by $7 sequentially, driven by approximately $8 per treatment of new costs associated with phosphate binders [21] Business Line Data and Key Metrics Changes - Adjusted international operating income increased by $29 million compared to the fourth quarter, with strong performance across various markets [22] - Integrated Kidney Care (IKC) reported operating losses of $29 million, in line with expectations, with seasonally stronger performance anticipated in the second half of the year [22] Market Data and Key Metrics Changes - Treatments per day declined by 40 basis points compared to Q1 2024, primarily due to a higher missed treatment rate caused by a severe flu season [19] - The company expects an approximately 50 basis point decline in treatments for the year, influenced by flu-related impacts and a cyber incident [20] Company Strategy and Development Direction - The company remains committed to investing available capital in innovation and high-return growth opportunities, including a recent acquisition in Latin America [13] - The capital allocation strategy includes returning capital to shareholders through share repurchases, with approximately $680 million repurchased since the last earnings call [13] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of operations despite a cybersecurity incident that disrupted parts of the business, with uninterrupted patient care maintained [9][10] - The company reiterated its 2025 guidance range for adjusted operating income and adjusted EPS, despite headwinds from the cyber incident and a challenging flu season [16][25] Other Important Information - The company launched a community-based collaboration with the YMCA to support chronic kidney disease education and prevention, with early results showing 30% of participants screened had previously undiagnosed CKD [6][7] - The majority of costs related to the cyber incident are expected to be one-time items recognized in the second quarter [31] Q&A Session Summary Question: Impact of flu and cyber attack on treatment growth - Management indicated that the flu had a more significant impact on the full year guidance, with the census decline in Q1 affecting the full year [29] Question: Costs related to the cyber attack - Management clarified that some costs will be direct and non-GAAP, likely covered by insurance, while others will flow through the P&L and are included in guidance [31] Question: Phosphate binders uptake and drug mix - The mix leaned towards iron-based binders, leading to an adjustment in guidance to the upper end of the previous range [33] Question: Revenue per treatment and managed care increases - Management confirmed that revenue per treatment guidance remains unchanged, with increases expected from both core business and oral medications [42] Question: IKC patient treatment and competitive pricing - Management noted that the financials are playing out as expected, with a disciplined approach to patient care and financial modeling despite competitive pressures [51] Question: International performance outlook - International operations had a strong quarter, with positive contributions from various markets and a successful acquisition [57]

Financial Performance - Total consolidated revenues for Q1 2025 were $3,224 million, a decrease of $71 million or 2.2% compared to Q4 2024 [104]. - U.S. dialysis revenues decreased by $65 million or 2.3% to $2,823 million in Q1 2025 compared to Q4 2024 [113]. - Operating income for Q1 2025 was $439 million, down $126 million or 22.3% from Q4 2024 [104]. - U.S. dialysis operating income for Q1 2025 was $476 million, a decrease of $20 million (4.0%) compared to Q4 2024 [128]. - The adjusted operating income for the same period was $439 million, reflecting a decrease from $491 million in the previous quarter [176]. - Income before income taxes attributable to DaVita Inc. for the three months ended March 31, 2025, was $217 million, down from $324 million in the previous quarter [179]. - Net income attributable to noncontrolling interests decreased to $69 million, down $21 million (23.3%) from Q4 2024 [145]. - Net income attributable to noncontrolling interests increased by $3 million (4.5%) in Q1 2025 compared to Q1 2024, driven by increased profitability at certain U.S. dialysis partnerships [153]. Treatment Volumes and Admissions - In Q1 2025, treatment per day volumes were approximately flat compared to Q4 2024, with revenue and treatment volume negatively impacted by a severe flu season and severe weather events [95]. - New-to-dialysis admission rates were strong in Q1 2025, but future revenues and treatment volumes may be adversely affected by elevated mortality levels in the ESKD and CKD populations [95]. - Dialysis treatments in Q1 2025 totaled 7,040,519, a decrease of 238,086 treatments or 3.3% from Q4 2024 [109]. Expenses and Costs - The company experienced increased expenses due to inflationary pressures and a challenging healthcare labor market, which are expected to continue [96]. - Total operating expenses for Q1 2025 were $2,347 million, a decrease of $45 million or 1.9% from Q4 2024 [118]. - Patient care costs per treatment increased by $7.17 or 2.7% to $271.77 in Q1 2025 compared to Q4 2024 [118]. - General and administrative expenses decreased by $33 million or 10.4% to $283 million in Q1 2025 compared to Q4 2024 [118]. Cybersecurity Incident - A ransomware incident occurred on April 12, 2025, leading to operational disruptions, although the company has prioritized minimizing disruption to dialysis care [97]. - The company is currently assessing the impact of the cybersecurity incident, including potential liabilities and the extent of data exfiltration [98][99]. - The company is actively working to restore functions affected by the cybersecurity incident, but the full impact remains uncertain [100]. Strategic Initiatives - The company is focused on implementing strategies related to integrated kidney care (IKC) and value-based care (VBC) initiatives [94]. - The incorporation of phosphate binders into the ESRD PPS bundle is expected to positively impact revenues during the TDAPA period, which is anticipated to last at least two years [117]. - The company expects to add additional service offerings and pursue strategic initiatives in the future, including healthcare services not related to kidney disease [132]. Cash Flow and Debt - Net cash provided by operating activities increased to $180 million in Q1 2025, a $315 million improvement compared to a net cash outflow of $135 million in Q1 2024 [155]. - Free cash flow improved by $282 million (86.2%) in Q1 2025, resulting in a cash outflow of $45 million compared to $327 million in Q1 2024 [159]. - Debt expense for Q1 2025 was $135 million, a decrease of $4 million (2.9%) compared to Q4 2024 [145]. - Debt expense for Q1 2025 increased by $36 million (36.4%) compared to Q1 2024, primarily due to an increase in the weighted average effective interest rate from 4.51% to 5.60% [148]. Operational Changes - Increased union organizing activities have been reported in nine clinics in California, which may impact operational stability [96]. - The number of U.S. dialysis centers operated decreased slightly from 2,675 to 2,661, while international centers increased from 427 to 512 [162]. - The company has outstanding letters of credit totaling approximately $173 million as of March 31, 2025 [183]. - The company entered into purchase agreements to acquire dialysis service operations in Chile, Ecuador, Colombia, and Brazil, with an expected cash payment of approximately $100 million for the Brazil transaction [185]. - The company has potential obligations to purchase noncontrolling interests in majority-owned dialysis partnerships, which are exercisable at the discretion of third-party owners [182]. Tax and Other Financial Metrics - Effective income tax rate attributable to DaVita Inc. increased to 24.9% in Q1 2025 from 19.9% in Q4 2024 [145]. - The effective income tax rate attributable to DaVita Inc. increased to 24.9% in Q1 2025 from 21.5% in Q1 2024, reflecting changes in tax benefits recognized [152]. - Other loss, net increased by $5 million (38.5%) in Q1 2025 compared to Q1 2024, primarily due to increased net losses on investments [150].

Financial Performance - DaVita Inc. reported consolidated revenues of $3.224 billion for the first quarter of 2025, with a net income of $163 million, down from $259 million in the previous quarter[5][3]. - The diluted earnings per share for the quarter was $2.00, compared to $3.09 in the fourth quarter of 2024 and $2.65 in the first quarter of 2024[3][5]. - Operating income for the quarter was $439 million, representing a margin of 13.6%, down from 17.2% in the previous quarter[4][5]. - Total revenues for Q1 2025 were $3,223,529 thousand, compared to $3,070,555 thousand in Q1 2024, reflecting an increase of 5.0%[21]. - Net income attributable to DaVita Inc. decreased to $162,917 thousand in Q1 2025 from $239,649 thousand in Q1 2024, a decline of 32.0%[21]. - Basic earnings per share attributable to DaVita Inc. fell to $2.05 in Q1 2025, down from $2.73 in Q1 2024, a decrease of 25.0%[21]. - Operating income for Q1 2025 was $438,937 thousand, compared to $483,845 thousand in Q1 2024, a decrease of 9.3%[21]. - The company reported a net decrease in cash of $(355,252) thousand in Q1 2025, compared to a decrease of $(33,853) thousand in Q1 2024[26]. - For the twelve months ended March 31, 2025, DaVita Inc. reported a net income attributable to the company of $860 million, compared to $936 million for the previous quarter and $816 million for the same period last year[36]. Treatment and Patient Care - Total U.S. dialysis treatments for the first quarter were 7,040,519, averaging 91,793 treatments per day, with a normalized non-acquired treatment growth of (0.6)% year-over-year[6]. - Revenue per treatment increased to $400.14, up $4.27 from the previous quarter and $15.60 from the same quarter last year[7]. - Patient care costs per treatment rose to $271.77, an increase of $7.17 from the previous quarter and $16.64 year-over-year[7][8]. - As of March 31, 2025, DaVita provided dialysis services to approximately 282,000 patients across 3,173 outpatient dialysis centers[13]. - U.S. dialysis patient service revenues were $2,817 million in Q1 2025, compared to $2,881 million in Q4 2024 and $2,750 million in Q1 2024[30]. - The number of treatments in Q1 2025 was 7,040,519, a decrease of 3.3% from 7,278,605 in Q4 2024 and a slight increase from 7,151,512 in Q1 2024[30]. Cash Flow and Expenses - Net cash provided by operating activities was $180,009 thousand in Q1 2025, compared to a net cash used of $(134,836) thousand in Q1 2024[26]. - Cash, cash equivalents, and restricted cash at the end of Q1 2025 totaled $524,573 thousand, compared to $430,781 thousand at the end of Q1 2024, an increase of 21.8%[26]. - Total operating expenses increased to $2,784,592 thousand in Q1 2025 from $2,586,710 thousand in Q1 2024, an increase of 7.6%[21]. - Operating cash flow for Q1 2025 was $180 million, significantly lower than $548 million in Q4 2024 and a turnaround from $(135) million in Q1 2024[32]. - Free cash flow for Q1 2025 was $(45) million, compared to $281 million in Q4 2024 and $(327) million in Q1 2024[32]. Debt and Leverage - Total debt increased to $9,799 million in Q1 2025 from $9,511 million in Q4 2024, with a leverage ratio of 3.27x[32]. - The total debt as of March 31, 2025, was $9,799 million, up from $9,511 million at December 31, 2024, and $9,179 million at March 31, 2024[36]. - The leverage ratio as of March 31, 2025, was 3.27x, compared to 3.03x in the previous quarter and 3.29x a year ago, remaining below the maximum permitted leverage ratio of 5.00x[36]. Share Repurchase and Guidance - DaVita repurchased 3.7 million shares for $550 million during the first quarter, at an average price of $148.94 per share[10]. - The company has a guidance for adjusted operating income between $2.010 billion and $2.160 billion for 2025, with adjusted diluted net income per share projected between $10.20 and $11.30[16]. - The company reported interest expenses of $437 million for the twelve months ended March 31, 2025, compared to $407 million in the previous quarter and $353 million in the same period last year[36]. Tax and Non-GAAP Measures - The effective income tax rate on income attributable to DaVita Inc. was 24.9% for the first quarter of 2025[12]. - The effective income tax rate on income attributable to DaVita Inc. increased to 24.9% for the three months ended March 31, 2025, compared to 19.9% in the previous quarter[55]. - The company’s management believes that the presentation of non-GAAP measures, such as adjusted operating income and adjusted net income, enhances understanding of the company's performance over time and relative to competitors[43].

Core Insights - DaVita Inc. reported strong financial performance for Q1 2025, emphasizing the stability of its operating model and commitment to shareholder value [1][2]. Financial Performance - Net income for Q1 2025 was $163 million, down from $240 million in Q1 2024, with diluted earnings per share at $2.00 compared to $2.65 in the previous year [1][19]. - Operating income decreased to $439 million, with an operating margin of 13.6%, down from 17.2% in Q4 2024 and 15.8% in Q1 2024 [2][23]. - Total consolidated revenues reached $3.224 billion, an increase from $3.071 billion in Q1 2024 [19][23]. Cost and Expense Analysis - Patient care costs per treatment rose to $271.77, up from $255.13 in Q1 2024, while general and administrative expenses were $374 million, compared to $362 million in the same period last year [4][25]. - The increase in costs was primarily driven by higher pharmaceutical expenses, particularly for phosphate binders, and compensation expenses [5][6]. Dialysis Metrics - Total U.S. dialysis treatments for Q1 2025 were 7,040,519, averaging 91,793 treatments per day, reflecting a slight increase of 0.01% from Q4 2024 [3][24]. - Normalized non-acquired treatment growth was reported at (0.6)% compared to Q1 2024 [3][24]. Share Repurchase Activity - The company repurchased 3.7 million shares for $550 million at an average price of $148.94 per share during Q1 2025 [8][26]. - Subsequent to Q1, an additional 1.7 million shares were repurchased for $259 million [8]. Integrated Kidney Care Metrics - As of March 31, 2025, DaVita had approximately 62,100 patients in risk-based integrated care arrangements, representing an annualized medical spend of about $5.2 billion [12][24]. Cash Flow and Capital Structure - Operating cash flow for Q1 2025 was $180 million, a significant improvement from a cash outflow of $135 million in Q1 2024 [9][26]. - Free cash flow was reported at $(45) million, compared to $(327) million in the same period last year [9][26]. Outlook - The company provided guidance for 2025, projecting adjusted operating income between $2.010 billion and $2.160 billion, and adjusted diluted net income per share between $10.20 and $11.30 [14].

Core Viewpoint - DaVita Inc. is set to report its first-quarter 2025 results, with expectations of revenue growth driven by improved revenue cycle operations, despite challenges in patient admissions and treatment volume [1][2][4]. Financial Performance - In the last reported quarter, DaVita's EPS was $2.24, exceeding the Zacks Consensus Estimate by 1.4%, with an average earnings surprise of 5.4% over the trailing four quarters [1]. - For Q1 2025, the Zacks Consensus Estimate for revenues is $3.21 billion, reflecting a 4.6% increase from the prior year, while the EPS estimate is $1.75, indicating a 26.5% decline year-over-year [5]. Operational Factors - Management highlighted that innovation in revenue cycle operations has led to higher revenue per treatment, which has helped offset slower treatment volume recovery [2]. - DaVita has closed three of four acquisitions in Latin America, with the final acquisition in Brazil expected to close mid-2025, contributing to future growth [3][17]. Challenges - The company is facing elevated mortality and mistreatment rates, and new patient starts have been negatively impacted by supply constraints in peritoneal dialysis solutions [4]. - The temporary closure of Baxter's North Cove facility due to Hurricane Helene has further hindered new patient admissions, which is expected to affect volume growth in 2025 [4][19]. Market Performance - Over the past three months, DaVita's shares have declined by 17%, underperforming its sector and peers [8][10]. - The company's forward price-to-sales (P/S) ratio is 0.8X, significantly lower than the industry average of 2.8X, indicating a potential undervaluation relative to expected sales growth [11][12]. Long-Term Outlook - The transition of oral drugs to the dialysis benefit under Medicare is expected to expand patient access and drive long-term revenue growth [13][16]. - Proposed updates to the Medicare ESRD payment system could increase reimbursement rates by 2.1% in 2025, aiding in patient coverage expansion [18]. Investment Considerations - DaVita's strong core business and financial stability suggest potential for future gains, but the current valuation indicates it may be prudent to hold rather than add new positions [20][21].

Company Performance - DaVita HealthCare (DVA) closed at $143.96, reflecting a +0.94% increase from the previous day's close, outperforming the S&P 500's daily gain of 0.44% [1] - The stock has decreased by 0.9% over the past month, underperforming the Medical sector's gain of 1.16% and the S&P 500's gain of 10.62% [1] Upcoming Earnings - The upcoming earnings report for DaVita HealthCare is scheduled for May 12, 2025, with an expected EPS of $1.75, indicating a 26.47% decline compared to the same quarter last year [2] - The consensus estimate for quarterly revenue is $3.21 billion, representing a 4.59% increase from the previous year [2] Annual Forecast - Zacks Consensus Estimates project earnings of $10.76 per share and revenue of $13.46 billion for the entire year, reflecting changes of +11.16% and +5.05%, respectively, compared to the previous year [3] Analyst Revisions - Recent revisions to analyst forecasts for DaVita HealthCare are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] Zacks Rank and Valuation - DaVita HealthCare currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [6] - The company is trading at a Forward P/E ratio of 13.25, which is lower than the industry average Forward P/E of 21.23 [7] - The PEG ratio for DaVita HealthCare is 1.05, compared to the industry average PEG ratio of 1.91 [8] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita HealthCare, has a Zacks Industry Rank of 53, placing it in the top 22% of over 250 industries [9]

Company Overview - DaVita Inc. is a health care provider focused on transforming care delivery to improve quality of life for patients globally [2] - The company has been a leader in clinical quality and innovation for 25 years, providing comprehensive kidney care [2] - As of December 31, 2024, DaVita served approximately 281,100 patients at 3,166 outpatient dialysis centers, with 2,657 centers in the United States and 509 centers in 13 other countries [2] Upcoming Events - DaVita will hold its quarterly conference call to discuss first quarter results on May 12, 2025, at 5:00 p.m. Eastern Time [1] - The results will be released after market close on the same day, and the call will be accessible via webcast [1] - Investors can join the call using the provided dial-in numbers and will need to provide the password "Earnings" [1]